Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001829126-25-001429
Filing Date
2025-03-04
Accepted
2025-03-04 10:32:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 9819
  Complete submission text file 0001829126-25-001429.txt   11468
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Subject) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-80136 | Film No.: 25702006
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address LEVEL 10, TOWER 11, AVENUE 5, NO. 8 JALAN KERINCHI, BANGSAR SOUTH WILAYAHPERSEKUTUANKUALA LUMPUR N8 59200
Business Address
Doris Wong Sing Ee (Filed by) CIK: 0001892421 (see all company filings)

Type: SCHEDULE 13D